Home Stock

Stock Research: UCB

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

UCB

BRU:UCB BE0003739530
72
  • Value
    57
  • Growth
    56
  • Safety
    Safety
    70
  • Combined
    67
  • Sentiment
    58
  • 360° View
    360° View
    72
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

UCB SA is a biopharmaceutical and specialty chemical company specializing in central nervous system (CNS) and immunology diseases. Its main business includes CNS disorders like epilepsy and immunology disorders such as rheumatoid arthritis. UCB SA operates globally, with a focus on Europe and North America. In the last fiscal year, the company had a market cap of $39,605 million, profits of $4,555 million, revenue of $6,369 million, and 9378 employees.

more

ANALYSIS: With an Obermatt 360° View of 72 (better than 72% compared with alternatives), overall professional sentiment and financial characteristics for the stock UCB are above average. The 360° View is based on consolidating four consolidated indicators, with all four indicators above average for UCB. The consolidated Value Rank has an attractive rank of 57, which means that the share price of UCB is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 57% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 56, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The company is also safely financed with a Safety rank of 70. Finally, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 58. ...read more

more
Strongest Rank Capital Growth
Weakest Rank Revenue Growth
Country Belgium
Industry Pharmaceuticals
Size Small
Website ucb.com
Index
BEL20
UCB stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 17-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
57 6 79 74
Growth
56 90 89 19
Safety
Safety
70 24 24 38
Sentiment
58 61 10 38
360° View
360° View
72 37 45 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
64 49 36 49
Opinions Change
50 59 24 48
Pro Holdings
n/a 45 14 56
Market Pulse
34 69 47 27
Sentiment
58 61 10 38
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
57 6 79 74
Growth
56 90 89 19
Safety Safety
70 24 24 38
Combined
67 24 82 32
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
51 11 46 54
Price vs. Earnings (P/E)
45 15 54 71
Price vs. Book (P/B)
64 21 81 78
Dividend Yield
48 32 70 65
Value
57 6 79 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
81 94 54 6
Profit Growth
78 54 77 48
Capital Growth
18 56 76 21
Stock Returns
45 96 52 54
Growth
56 90 89 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
49 61 48 43
Refinancing
49 18 23 24
Liquidity
77 31 40 56
Safety Safety
70 24 24 38

Similar Stocks

Discover high‑ranked alternatives to UCB and broaden your portfolio horizons.

Fresenius

GER:FRE
Country: Germany
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Strabag

VIE:STR
Country: Austria
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Yara International

OSL:YAR
Country: Norway
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is an all-around strong stock. It shows good value, high growth, safe financing, and positive professional sentiment. It is ideal for most buy-and-hold investors who value a good all-around stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews